ADDENDUM TO CLINICAL STUDY AGREEMENT ("Addendum 1")

This Addendum to Financial Agreement ("Agreement") is executed as of this the gran day of 3 n 2017 ("Effective Date") by and between:

1 PREAMBLE AND INTENTION

The Parties are.

 Sun Pharma Advanced Research Company Ltd. (CINL73100GJ2006PLC047837),a company registered under the Companies Act, 1956 having its registered office at SPARC Ltd, Akota Road, Akota, Vadodara – 390020 India and having a business address at 17/B, Mahakali Caves Road, Andheri East, Mumbai 400093, India, which expression shall, where the context so permits include his successors in office and assigns (hereinafter referred to as the "Sponsor").

AND

 Mahatma Gandhi Mission's Medical College & Hospital, a nospital having its registered office at N-6 CIDCO, Aurangabad-431 003, Maharashtra, India, which expression shall, where the context so permits include his successors in office and permitted assigns (hereinafter referred to as the "Institution").

AND

3. **Dr. Chandrashekhar Tamane**, MBBS, MD (Oncology), Principal Investigator, at Mahatma Gandhi Mission's Medical College & Hospital, N-6 CIDCO, Aurangabad-431 003, Maharashtra, India (hereinafter referred as the "Investigator")

(Each a "Party" and collectively, the "Parties")

WHEREAS:

- 1.1 The Parties entered into a Clinical Study Agreement dated 9th day of August 2016 (the "Agreement").
- 1.2 The Parties wish to amend and supplement certain of the terms and conditions of the Agreement as recorded herein ("Addendum 1").
- 1.3 This addendum is prepared to outline the financial grant section for the Hospitalization, Local Laboratory, and Chemoport/Central line expenses in accordance with the current legislations in India; and incorporate certain changes in the Schedule A.
- 1.4 This Addendum 1 forms part of and is to be read with the Agreement as from the date of the last signature hereof ("Effective Date")

2 AMENDMENTS

The Parties hereby amend the Agreement as recorded in Schedule A hereto.

X

3 GENERAL

- 3.1 As of the Effective Date, this Addendum 1 shall be read together with and shall be deemed to be incorporated in the Agreement and shall be governed by the terms, conditions and definitions set forth in the Agreement, as if such terms were fully set forth herein.
- 3.2 Except as expressly amended hereby, the terms and conditions of the Agreement shall continue in full force and effect and are hereby confirmed and ratified.
- 3.3 If there is inconsistency between the provisions of the Agreement and this Addendum 1, the provisions of this Addendum 1 shall prevail.

Place:

4 SIGNATORIES

Signature:

Designation:

Name:

Date:

Place:

Sun Pharma Advanced Research Company Ltd. Mahatma Gandhi Mission's Medical College

y Sing Solar

& Hospital

Signature:

Dr. Rajendra Bohra

Designation:

Dean

Date:

Ol Feb 2517

Mahatma Gandhi Mission's Medical College &Hospital

Mr Ajay Singh Solanki

Sr.GM, Clinical Operations

81. Jan. 2017

Signature:

Name: Dr. Chandrashekhar Tamane

Mumbai

Designation: Principal Investigator

Date: 01 Feb 2017

Place: Autangabad

KS



Autangabas

SCHEDULE A

AMENDMENTS TO THE AGREEMENT

Financial Grant

Protocol No.: CLR_16_13

Protocol Title: "A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) and Abraxane®

in Subjects with Locally Recurrent or Metastatic Breast Cancer."

Investigator's Name: Dr. Chandrashekhar Tamane

Institute Name: Mahatma Gandhi Mission's Medical College & Hospital

Heads	Amount in INR mentioned in Executed CSA Version 01	Amount in INR with breakup	Schedule
Haematology (Haemoglobin, TLC, DLC, ANC, Platelets) Clinical chemistry Liver function tests (AST, ALT, AP, total bilirubin, serum albumin) Renal function tests (BUN/urea, serum creatinine)	As per actual	Haematology: Rs 240 Clinical Chemistry: Rs 540+Rs 350+ Rs 420	Monthly
Electrolytes (serum Na+, K+, Cl-)		Total: Rs 1550	
ECG	=	ECG: Rs 300	
Hospitalization charges (Per Day)	As per actual	Rs 2950	Monthly
Central line/Chemoport charges	Not Mentioned	Chemoport charges- 40,000	Monthly
	^	Central Line charges: Rs. 5000	

All invoices will be addressed to: Mr. Ashok Gupta, Sun Pharma Advanced Research Company Ltd., Clinical Research Dept, 17/B, Mahal industrial Estate, Mahakali Caves Road, Andheri (E), Mumbai 400093, Maharashtra, India.